Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcumin + QingDai is a combination of two herbal compounds—curcumin (the active ingredient in turmeric) and QingDai (also known as Indigo or derived from *Indigofera tinctoria*). This nutraceutical blend has been studied for the treatment of moderate to severe ulcerative colitis (UC), particularly in patients who have failed conventional therapies. Clinical trials and real-world studies indicate that the combination can induce clinical response and remission in active UC, with notable efficacy even among patients refractory to biologics or immunomodulators[1][2][3][4]. The mechanism of action appears to involve activation of the aryl-hydrocarbon receptor pathway in colonic mucosa, which may trigger a natural inflammation-control switch distinct from immune suppression[4]. The product is standardized for medical use with controlled levels of indigo and indirubin. All adverse events reported were reversible upon discontinuation of QingDai[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on curcumin + qingdai.